Get started

MSB

DoDo's Clean Market Structure Break. I saw a really interesting chart from MartyBanks about DoDo, I've linked it in the related ideas. So I decided to look back and chart DoDo. After a massive dump it found support on the weekly level and more recently bouncing from daily support. From there we had a clear market structure break on the daily. You could make a case and say that we actually had two market structure breaks on the daily timeframe and formed a daily order block at the .489 level. The 9day ema cross of the 21day ema also shows signs of bullishness. I'm now waiting for a retest to enter. Targets are .518, .500 and .481. I recommend watching the idea linked to get a better grasp of the situation.
Long
by CViewsTH
3
Sentinel One: Retest and Fly. Sentinel One is a a relatively young cyber security company which had it's IPO last June. It was safe to say the IPO went well, it was the highest-valued cyber security stock IPO. 40.3 was the lowest price wicked to, that's the area of monthly support we're essentially at today. Cyber-Security is a fascinating space, S is a chart to keep your eyes on if you have interest in a developing stock in this sector. S found its all time low recently at around 29 dollars. Volume surged at that price and even more so at the 35-38 dollar area. I'm looking to enter if we get a good retest from here. My targets are: 33.5, 32.2, and 31 dollars. Take profits are outlined in the chart, 46, 51, and 56 dollars. If we go below 28 dollars I will plan to exit the trade.
NYSE:SLong
by CViewsTH
Where's the Rice. Rice is an integral part of life in many countries, particularly the ASEAN region. It also plays a key role in the economies in the some of world's most populated regions. Countries like Malaysia have seen annual growth in exports of 6.3% annually over the last decade. Rice exporting leaders in the region, Thailand and Vietnam, have also maintained small growth in exports. Statistics show that the consumption of rice within the ASEAN region is also increasing. According to Ricepedia, 640 million tons of rice is grown in Asia, 90% of the global supply. In 2010/2011 China imported 540,000 metric tons and exported 500,000 metric tons of rice. Ten years later imports swelled to 800,000 metric tons while exports doubled to 100,800 metric tons of rice. I think getting invested in rice after its next big dip, whenever that is, may be a good idea. Being interested in the business of food I wanted to have a look at how Rice's price action has looked in years past. I did a little bit of wave analysis here. Let me know where you think we are. I drew the weekly Fib range retracement and found that a good trade on the larger time frame has taken place with the optimal entry fibs hit and target met. To get a better understanding of how price moved in the past I noted key Market Structure Breaks on this chart here. They help me find potential OBs and FVGs and potential areas of confluence. Here is the same wave count but shown on the weekly time frame. Overall I'm interested in the food sector as an area of investment. Rice was one of the first things that came to mind. Looking forward to doing more research on this. Let me know what you think!
CBOT:ZR1!
by CViewsTH
1
BTCUSD Potential Reversal?Right Now, BTCUSD is seemingly in the long term bull trend. On 4H, We see a clear bullish divergence. Though the divergence alone is not a confirmation of a reversal and bull trend continuation, the fact that BTCUSD price is near the major trendline on Daily Chart as suggested in the previous analysis (), and piercing the resistance line on H4 combined give enough reason to stay on bullish bias. Right now, we need to break and retest the resistance line on 4H to get a confirmation. Regards, Muzammil Shaikh Bismil
BITSTAMP:BTCUSDLong
by msbismil
4
BTCUSD Possible Scenarios?BTCUSD is currently in a long term Bull run. Currently, the asset is undergoing a decisive movement. The trendline shows we have almost bottomed out. A little downward movement further towards the 50K-52K level making our trend still valid on 1D Chart. Since we are completing the 4th Elliot Wave , it is a very good chance to take a long position, managing the stop loss somewhere below the trendline near 45K Level. Contrary to the Bull Run Continuation, we might break the trendline, retest it and we go to the next major support around 30K Level as indicated in the chart. I will keep updating this analysis as we progress. Please feel free to give your opinion.
BITSTAMP:BTCUSD
by msbismil
1
MSB - Trade PlanMSB has been consolidating until recently when it spiked higher and pulling back currently. This could be a buying opportunity as long as its 50SMA support holds. I will be watching price action at the current levels and targeting the upper Resistance level of $2.95 with a tight stoploss below the swing low or the 50SMA at $1.80. Please note these are my own notes, by no means trading advice. Please do your own research before entering into any trade.
ASX:MSBLong
by AsimMirzaTrader
2
MSB - Bullish (A Medium to Long Term Buying Opportunity)1. Price has plummeted down and stopped at exact upward sloping 50 Months Moving Average 2. Price got support exactly on the 200 Weeks Moving Average 3. Price got support at a very strong Monthly Support Level I believe this is a great medium to long term buying buying opportunity, as price got supported at many confluence levels, as this might be a Higher Low on the Monthly and the Weekly Chart. The support level of $2.00 is very strong. As price got dumped aggressively, I believe it will take some time for it to move up very quickly. I think price will consolidate and coil and there will be a lot of accumulation which may take time for price to take off. I will be watching price action and will enter once bullish price action is confirmed. Please note these are my own notes, by no means trading advice. Please do your own research before entering into any trade.
ASX:MSBLong
by AsimMirzaTrader
3
MSB - Updated AnalysisI hope you find my analysis useful. From what I can see, price seems to be holding within the trend channel (bullish sign) The moving averages are beginning to cross, and as you can see in the past, when that occurred, price rose (bullish sign). Price needs to hold above the lower trend channel and break past the .786 fib to confirm bullish price action. Stock is very news sensitive, price may rise in anticipation of an announcement and come crashing down if the announcement is lackluster. Trade with caution, but from what I'm seeing, right now is a good time to either average in or enter the trade for a decent risk-vs-reward scenario. *Not financial advice* *Just my opinion* *All investing and trading involves risk*
ASX:MSBLong
by TheTraderAndy
MESOBLAST (MSB) - FDA will likely approve Ryoncil (analysis)MSB is developing Ryoncil - an IV stem cell therapy for the treatment of acute graft versus host disease (aGVHD) in paediatrics. aGCHD is a potentially life threatening (up to 70-90% mortality) complication of bone marrow transplants (indicated for leukemia/lymphoma etc). Ryoncil has been accepted by the FDA for priority review with a PDUFA action date of US 30th September (1st Oct in AUS). Why might the FDA approve Ryoncil? Probability wise: - Oncology therapy's have an average 88% probability of being approved once they have been accepted for review (data averaged from results from Wong et al (2018), Thomas et al (2016), Hay et al (2014), and DiMasi et al (2010)). - As part of the review, the FDA requested a recommendation from the Oncologist Drugs Advisory Committee (clinical oncology academics and statisticians) who on Aug 13th voted 9:1 that the available data supports the efficacy of Ryoncil. - Ryoncil has been approved in Japan for the last 5 years with strong yoy growth. Benefit-risk ethics analysis: - There are no FDA approved treatments for aGCHD in pediatrics and no therapies are considered standard of care. - Ryoncil is effective vs placebo (28d survival 64% vs 38%, 100d survival 79% vs 54%). - Adverse Effects of Ryoncil were not statistically different from placebo. In fact unapproved treatments (steroids) carry high risk of toxicity. - aGCHD has a 70-90% mortality rate, there are no FDA approved treatments, Ryoncil appears to be effective, risk of doing harm by approving Ryoncil is low. It seems like the ethical decision is to approve Ryoncil. Why might not the FDA approve Ryoncil? - The FDA prefers double-blinded, placebo-controlled RCT's to show effectiveness. However, due to the high mortality rate of aGCHD, enrolling children into an RCT is clearly not ethical. I'd argue that the single arm study comparing to an external control population is as good as you're gonna get. It also does not need to be blinded as the primary endpoint is mortality. The 9:1 ODAC vote seems to support this. - The study was small (N=14, N=13). It might be reasonable for the FDA to ask for another (potentially larger) study to replicate the results which is a risk. - Quality control concerns. The FDA raised concerns that the way MSB measure the potency of the Ryoncil (CQA's) may not be enough to ensure the clinical effectiveness of the product. I'm no expert in this part but when MSB responded to these concerns in the webcast, they kind of just reiterated the CQA's from their manufacturing were very high but didn't really address the concern that the CQA's might not translate to clinical effectiveness. It might be reasonable for the FDA to ask for more data on this. - Even if more data is requested, Ryoncil can still be provisionally approved. Conclusion: The FDA will likely approve or provisionally approve (with the request of more data) Ryoncil therapy for pediatric aGVHD in the US which will strongly improve the revenue potential of MSB.
ASX:MSBLong
by Sean_Kenworthy
MSB – MESOBLAST LIMITED Targeting $5.35Hello Fellow Traders! The XJO (ASX200) has sold off from the peak made on August 25th following the SPX(US500) and Nasdaq during uncertain global times and Covid numbers starting to increase again in Europe. While the XJO continued to fall in the past 5 trading days, MSB has experienced supreme buying pressure continuing to retest $5.00. MSB is a Bio – Pharmaceutical company that offers products in the area of cardiovascular, spine orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. Key Points: - Price holding above the 200 EMA - Price holding above the 50 EMA - Bullish wedge pattern below range break out - Fibonacci 61.8% level providing support at $5.00 - Volume increasing showcasing buyers’ momentum - RSI also breaking trendline - Superior risk to reward - SPX and NAS100 both in the green overnight Key Levels: Support - 5.00, 50 EMA, 200 EMA Resistance – 5.25, 5.35 Entry Zone: Optimal entry provides the greatest reward to risk ratio while supporting entry is a zone for reversal signals. Optimal Entry – 5.05 Supporting Entry – 5.10 Candle Reversals for entry - Bullish Hammer - Bullish Engulfing - Bullish Piercing The Risk: As traders, it is your job to mitigate the risk and only trade structures that provide high probability and great reward to risk ratios. If you are not comfortable with defined exit levels, experiment with Moving Averages to help set solid exit rules to protect your capital. IF: Price breaks below 5.00 and violates 50 EMA– this would suggest the structure is not in our favour and would be wise to reduce exposure or close the trade until a solid signal gives us reasons to re-enter. Reward / Reward Targets: Optimal Entry $5.05 – Target 1 $5.25 = 3.3x Reward to Risk Optimal Entry $5.05 – Target 2 $5.35 = 5x Reward to Risk Supporting Entry 5.10 – Target 1 $5.25 = 1.6x Reward to Risk Supporting Entry 5.10 – Target 2 $5.35 = 2.6x Reward to Risk
ASX:MSBLong
by tradetheday